66.25 -0.49 (-0.73%)
After hours: 6:01PM EST
|Bid||66.26 x 800|
|Ask||67.39 x 800|
|Day's Range||63.21 - 67.39|
|52 Week Range||26.40 - 74.81|
|Beta (3Y Monthly)||0.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||77.83|
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today announced that management will be attending the following upcoming inve
Tandem Diabetes Care Inc (NASDAQ: TNDM) shares traded lower Friday after a report of the death of a patient using Tandem’s T:SLIM X2 insulin pump was added to the Food and Drug Administration’s Adverse Event report system. A Tandem spokesman said the company couldn’t comment in detail because of health privacy rules, but did say the cause of death “was not due to insulin delivery or pump malfunction.
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2019 and updated its financial guidance for the year ending December 31, 2019.
Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, is supporting the efforts of Beyond Type 1, a global diabetes advocacy organization, in fielding its largest marathon team in history, made up of 30 runners with a combined 385 years of experience living with type 1 diabetes. The Beyond Type Run team will be running the TCS New York City Marathon on November 3, 2019, and Tandem Diabetes Care has made the t:slim X2™ insulin pump with Basal-IQ® technology available to all team members.
AmerisourceBergen's (ABC) Q4 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced presentation of real-world data from pediatric users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend technology at the 45th annual conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD). Data from 2,696 users under the age of 18 years old showed an overall rate of hypoglycemia of only 0.9 percent when using Basal-IQ technology. A subgroup of users with at least 21 days of sensor-augmented pump data prior to use of Basal-IQ technology demonstrated a 31 percent reduction in hypoglycemia following introduction of the feature (n=491).
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
In this daily bar chart of TNDM, below, we can see that prices have been stuck in an eight month sideways consolidation pattern. The daily On-Balance-Volume (OBV) line has been in a slow rise from early July telling us that buyers of TNDM have been more aggressive and buying shares even when prices declined. In this weekly bar chart of TNDM, below, we can see that prices have had a big rally in the past two years.
Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced publication by the New England Journal of Medicine (NEJM) of results from the landmark Protocol 3 study (DCLP3) of the National Institutes of Health (NIH)-funded International Diabetes Closed Loop (iDCL) trial using the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed-loop technology. Over the six-month study period, use of Control-IQ technology led to a higher percentage of time spent in range (70-180 mg/dL), less hyper- and hypoglycemia and better HbA1c levels than use of a sensor augmented pump. The t:slim X2 insulin pump with Control-IQ technology, currently under review by the U.S. Food and Drug Administration (FDA), utilizes Dexcom G6 continuous glucose monitoring (CGM) sensor values to predict glucose levels 30 minutes ahead and adjust insulin delivery to help prevent highs and lows, while still allowing the user to manually bolus for meals.
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
DexCom shares fell Tuesday after rival Tandem Diabetes Care said it was partnering with Abbott Labs to develop a new insulin pump featuring Abbott's glucose-sensing technology. Tandem and Abbott "can provide new ways for people to manage their diabetes" that "can integrate easily into their daily lives, especially people who rely on insulin pumps," Abbott Vice President Jared Watkin said in a statement. The partnership ends exclusivity for DexCom in the space and exposes 15% of the company's sales to competition, according to Bloomberg.
- Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes ABBOTT PARK, Ill. and SAN DIEGO , Oct. ...
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, plans to release its third quarter 2019 results after the financial markets close on Monday, November 4, 2019.
Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.